<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099694</url>
  </required_header>
  <id_info>
    <org_study_id>Jiulongpo People's Hospital</org_study_id>
    <nct_id>NCT03099694</nct_id>
  </id_info>
  <brief_title>NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS)</brief_title>
  <official_title>Noninvasive Ventilation for Preterm Neonates With Respiratory Distress Syndrome: a Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xingwang Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guiyang Maternity and Child Health Care Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yan'an Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou Children's Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Women's and Children's Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The People's Hospital of Dehong Autonomous Prefecture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kunming Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Three Gorges Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Provincial Maternity and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Women and Children Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiulongpo No.1 People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators compared advantages and disadvantages of two forms of noninvasive
      respiratory support —noninvasive high-frequency oscillatory ventilation (nHFOV) or nasal
      continuous positive airway pressure (nCPAP) —as a primary mode of ventilation in premature
      infants with RDS．
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Invasive mechanical ventilation is associated with development of adverse
      pulmonary and non-pulmonary outcomes in very low birth weight infants. Various modes of
      non-invasive respiratory support are being increasingly used to minimize the incidence of
      bronchopulmonary dysplasia (BPD). The aim of this trials to compare the effect of noninvasive
      high-frequency oscillatory ventilation (NHFOV) and nasal continuous positive airway pressure
      (NCPAP) in preterm infants with respiratory distress syndrome (RDS) as a primary noninvasive
      ventilation support mode.

      Methods/Design:In this multicenter, randomized, controlled trial, 300 preterm infants at
      gestational age (GA) less than 34 weeks with a diagnosis of RDS will be randomized to NHFOV
      or NCPAP as a primary mode of non-invasive respiratory support. Study will be conducted in 18
      tertiary neonatal intensive care units in China.

      The primary outcome is the need for invasive mechanical ventilation (IMV)during the first 7
      days after enrollment in preterm infants randomized to the two groups. The secondary outcomes
      include days of hospitalization, days on noninvasive respiratory support, days on IMV, days
      on supplemental oxygen, mortality, need for surfactant, incidence of retinopathy of
      prematurity(ROP) and bronchopulmonary dysplasia(BPD), occurrence of abdominal distention, air
      leaks, intraventricular hemorrhage (IVH ≥ grade 3) and necrotizing enterocolitis (NEC&gt; II
      stage). Other secondary outcomes include scores of Bayley Scales of Infant Development at 2
      months and 2 years of corrected age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Actual">July 28, 2018</completion_date>
  <primary_completion_date type="Actual">July 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Required Intubation</measure>
    <time_frame>during the first 7 days after birth</time_frame>
    <description>The criteria for endotracheal mechanical ventilation were as follows: severe respiratory acidosis (PaCO2 &gt; 60 mmHg with pH&lt;7.20), severe apnea and bradycardia (defined as recurrent apnea with &gt; 3 episodes per hour associated with heart rate &lt; 100/min, a single episode of apnea that required bag and mask ventilation), hypoxia (FiO2&gt;0.5 with PaO2＜50mmHg), severe respiratory distress, neonatal pulmonary hemorrhage, and cardiopulmonary arrest without effective resuscitation needing continued ventilation and rescue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Intraventricular Hemorrhage (IVH, ≥ Grade Ⅲ)</measure>
    <time_frame>first two months after birth</time_frame>
    <description>The criteria for intraventricular hemorrhage (IVH, ≥ grade Ⅲ): intraventricular hemorrhage with ventricular dilatation and intraventricular hemorrhage with paren- ehymal hemorrhage. Intraventricular hemorrhage (≥ grade Ⅲ) is worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Pneumothorax</measure>
    <time_frame>during non-invasive ventilation, up to 7 days</time_frame>
    <description>the incidence of pneumothorax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Neonatal Necrotizing Enterocolitis(&gt;Stage II)</measure>
    <time_frame>during non-invasive ventilation, up to 7 days</time_frame>
    <description>The criteria for neonatal necrotizing enterocolitis(&gt;stage II): Unequivocal malfunction of the gastrointestinal tract is demonstrated clinically and by radiographic evaluation. Other disorders such as malrotation and volvulus and Hirschsprung's disease must be excluded.
Neonatal necrotizing enterocolitis(&gt;stage II) is worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Retinopathy of Prematurity (&gt;Stage II)</measure>
    <time_frame>at a post-menstrual age of 36 weeks or at discharge</time_frame>
    <description>The criteria for Retinopathy of prematurity (&gt;Stage II); extraretinal fibrovascular proliferation neovascularization extends from ridge into the vitreous. Retinopathy of prematurity (&gt;Stage II) is worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Score of Bayley Scales of Infant Development</measure>
    <time_frame>30 months</time_frame>
    <description>scores of Bayley Scales of Infant Development at 2 months old and 2 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Bronchopulmonary Dysplasia(BPD)</measure>
    <time_frame>at a post-menstrual age of 36 weeks or at discharge</time_frame>
    <description>BPD was defined according to the National Institutes of Health consensus definition: Need for O2 supplementation(FiO2＞0.21) for at least 28 days after birth.
BPD is worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Abdominal Distention</measure>
    <time_frame>during non-invasive ventilation, up to 7 days</time_frame>
    <description>Abdominal circumference increase 2 centimeter during non-invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time of Non-invasive Ventilation</measure>
    <time_frame>during non-invasive ventilation, up to 30 days</time_frame>
    <description>Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>during hospitalization, up to 60 days</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predischarge Mortality</measure>
    <time_frame>during hospitalization, up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of O2 Therapy</measure>
    <time_frame>during hospitalization, up to 60 days</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thick Secretions Causing an Airway Obstruction</measure>
    <time_frame>during non-invasive ventilation, up to 15 days</time_frame>
    <description>determined by the clinician</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Preterm Infants</condition>
  <arm_group>
    <arm_group_label>nCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nasal continuous positive airway pressure (nCPAP) — as a primary mode of ventilation in premature infants with RDS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nHFOV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>noninvasive high-frequency ventilation (nHFOV)</intervention_name>
    <description>NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.</description>
    <arm_group_label>nHFOV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nasal continuous positive airway pressure (nCPAP)</intervention_name>
    <description>Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)</description>
    <arm_group_label>nCPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        (1)Gestational age (GA) is from 26 to 34 weeks; (2) diagnosis of RDS. The diagnosis of RDS
        will be based on clinical manifestations (tachypnea, nasal flaring and or grunting) and
        chest X-ray findings; (3) RDS Silverman score&gt;5; (4) informed parental consent has been
        obtained.

        Exclusion criteria

        (1) severe RDS requiring early intubation according to the American Academy of Pediatrics
        guidelines for neonatal resuscitation7; (2)major congenital malformations or complex
        congenital heart disease; (3) group B hemolytic streptococcus pneumonia, septicemia,
        pneumothorax, pulmonary hemorrhage; (4) cardiopulmonary arrest needing prolonged
        resuscitation; (5) transferred out of the NICUs without treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi Yuan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Third Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xingwang Zhu</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>October 7, 2018</results_first_submitted>
  <results_first_submitted_qc>June 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2019</results_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jiulongpo No.1 People's Hospital</investigator_affiliation>
    <investigator_full_name>Xingwang Zhu</investigator_full_name>
    <investigator_title>Director of neonatology</investigator_title>
  </responsible_party>
  <keyword>NRDS</keyword>
  <keyword>nHFOV</keyword>
  <keyword>nCPAP</keyword>
  <keyword>preterm infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Dr. Kris Sekar, Professor of Pediatrics, Oklahoma University Medical Center, Oklahoma, Dr. Jatinder Bhatia, Professor of Pediatrics, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia, and Dr. Rowena Cayabyab, MD., MPH (Biostatistics and Epidemiology) Assistant Professor of Pediatrics, Keck School of Medicine of the University of Southern California, Los Angeles, California will serve as DSMB members. Dr. Cayabyab will also serve as consultant for statistical analysis.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03099694/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03099694/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From May, 2017, through July, 2018, a total of 18 centers screened 2509 infants, of which 1385 were eligible. We recruited 340 infants (170 in each group), to account for dropouts. Finally, 302 infants completed the trial (152 in NHFOV; 150 in NCPAP group.)</recruitment_details>
      <pre_assignment_details>1045 Did not undergo randomization
663 Refused to participate
382 NHFOV devices not available</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>nCPAP</title>
          <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
        </group>
        <group group_id="P2">
          <title>nHFOV</title>
          <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>nCPAP</title>
          <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
        </group>
        <group group_id="B2">
          <title>nHFOV</title>
          <description>infants receive primary non-invasive respiratory support by mean of NIPPV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="302"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="1.8"/>
                    <measurement group_id="B2" value="30.6" spread="1.7"/>
                    <measurement group_id="B3" value="30.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multiple birth</title>
          <description>Mothers of infants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antenatal steroids</title>
          <description>Mothers of infants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cesarean delivery</title>
          <description>Mothers of infants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Premature rupture of membranes＞18h</title>
          <description>Mothers of infants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational diabetes mellitus</title>
          <description>Mothers of infants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1582" spread="343"/>
                    <measurement group_id="B2" value="1564" spread="367"/>
                    <measurement group_id="B3" value="1572" spread="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Required Intubation</title>
        <description>The criteria for endotracheal mechanical ventilation were as follows: severe respiratory acidosis (PaCO2 &gt; 60 mmHg with pH&lt;7.20), severe apnea and bradycardia (defined as recurrent apnea with &gt; 3 episodes per hour associated with heart rate &lt; 100/min, a single episode of apnea that required bag and mask ventilation), hypoxia (FiO2&gt;0.5 with PaO2＜50mmHg), severe respiratory distress, neonatal pulmonary hemorrhage, and cardiopulmonary arrest without effective resuscitation needing continued ventilation and rescue</description>
        <time_frame>during the first 7 days after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Intubation</title>
          <description>The criteria for endotracheal mechanical ventilation were as follows: severe respiratory acidosis (PaCO2 &gt; 60 mmHg with pH&lt;7.20), severe apnea and bradycardia (defined as recurrent apnea with &gt; 3 episodes per hour associated with heart rate &lt; 100/min, a single episode of apnea that required bag and mask ventilation), hypoxia (FiO2&gt;0.5 with PaO2＜50mmHg), severe respiratory distress, neonatal pulmonary hemorrhage, and cardiopulmonary arrest without effective resuscitation needing continued ventilation and rescue</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Intraventricular Hemorrhage (IVH, ≥ Grade Ⅲ)</title>
        <description>The criteria for intraventricular hemorrhage (IVH, ≥ grade Ⅲ): intraventricular hemorrhage with ventricular dilatation and intraventricular hemorrhage with paren- ehymal hemorrhage. Intraventricular hemorrhage (≥ grade Ⅲ) is worse outcome.</description>
        <time_frame>first two months after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Intraventricular Hemorrhage (IVH, ≥ Grade Ⅲ)</title>
          <description>The criteria for intraventricular hemorrhage (IVH, ≥ grade Ⅲ): intraventricular hemorrhage with ventricular dilatation and intraventricular hemorrhage with paren- ehymal hemorrhage. Intraventricular hemorrhage (≥ grade Ⅲ) is worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Pneumothorax</title>
        <description>the incidence of pneumothorax</description>
        <time_frame>during non-invasive ventilation, up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Pneumothorax</title>
          <description>the incidence of pneumothorax</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Neonatal Necrotizing Enterocolitis(&gt;Stage II)</title>
        <description>The criteria for neonatal necrotizing enterocolitis(&gt;stage II): Unequivocal malfunction of the gastrointestinal tract is demonstrated clinically and by radiographic evaluation. Other disorders such as malrotation and volvulus and Hirschsprung's disease must be excluded.
Neonatal necrotizing enterocolitis(&gt;stage II) is worse outcome</description>
        <time_frame>during non-invasive ventilation, up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Neonatal Necrotizing Enterocolitis(&gt;Stage II)</title>
          <description>The criteria for neonatal necrotizing enterocolitis(&gt;stage II): Unequivocal malfunction of the gastrointestinal tract is demonstrated clinically and by radiographic evaluation. Other disorders such as malrotation and volvulus and Hirschsprung's disease must be excluded.
Neonatal necrotizing enterocolitis(&gt;stage II) is worse outcome</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Retinopathy of Prematurity (&gt;Stage II)</title>
        <description>The criteria for Retinopathy of prematurity (&gt;Stage II); extraretinal fibrovascular proliferation neovascularization extends from ridge into the vitreous. Retinopathy of prematurity (&gt;Stage II) is worse outcome.</description>
        <time_frame>at a post-menstrual age of 36 weeks or at discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Retinopathy of Prematurity (&gt;Stage II)</title>
          <description>The criteria for Retinopathy of prematurity (&gt;Stage II); extraretinal fibrovascular proliferation neovascularization extends from ridge into the vitreous. Retinopathy of prematurity (&gt;Stage II) is worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Score of Bayley Scales of Infant Development</title>
        <description>scores of Bayley Scales of Infant Development at 2 months old and 2 years old</description>
        <time_frame>30 months</time_frame>
        <posting_date>09/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Bronchopulmonary Dysplasia(BPD)</title>
        <description>BPD was defined according to the National Institutes of Health consensus definition: Need for O2 supplementation(FiO2＞0.21) for at least 28 days after birth.
BPD is worse outcome.</description>
        <time_frame>at a post-menstrual age of 36 weeks or at discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Bronchopulmonary Dysplasia(BPD)</title>
          <description>BPD was defined according to the National Institutes of Health consensus definition: Need for O2 supplementation(FiO2＞0.21) for at least 28 days after birth.
BPD is worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Abdominal Distention</title>
        <description>Abdominal circumference increase 2 centimeter during non-invasive ventilation</description>
        <time_frame>during non-invasive ventilation, up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Abdominal Distention</title>
          <description>Abdominal circumference increase 2 centimeter during non-invasive ventilation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time of Non-invasive Ventilation</title>
        <description>Hours</description>
        <time_frame>during non-invasive ventilation, up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>The Time of Non-invasive Ventilation</title>
          <description>Hours</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="40.0" upper_limit="166.0"/>
                    <measurement group_id="O2" value="78.5" lower_limit="48.0" upper_limit="163.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospitalization</title>
        <description>Days</description>
        <time_frame>during hospitalization, up to 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospitalization</title>
          <description>Days</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="19.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="31.0" lower_limit="18.5" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predischarge Mortality</title>
        <time_frame>during hospitalization, up to 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>Predischarge Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of O2 Therapy</title>
        <description>Days</description>
        <time_frame>during hospitalization, up to 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
          </group>
        </group_list>
        <measure>
          <title>Length of O2 Therapy</title>
          <description>Days</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="4.0" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thick Secretions Causing an Airway Obstruction</title>
        <description>determined by the clinician</description>
        <time_frame>during non-invasive ventilation, up to 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>nCPAP</title>
            <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
          </group>
          <group group_id="O2">
            <title>nHFOV</title>
            <description>infants receive primary non-invasive respiratory support by mean of NIPPV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thick Secretions Causing an Airway Obstruction</title>
          <description>determined by the clinician</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>nHFOV</title>
          <description>infants receive primary non-invasive respiratory support by mean of nHFOV</description>
        </group>
        <group group_id="E2">
          <title>nCPAP</title>
          <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Shi Yuan</name_or_title>
      <organization>Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Key Laboratory of Pediatrics in Chongqing</organization>
      <phone>13508300283</phone>
      <email>15084335697@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

